| |
| |
Gene Symbol |
POLE3 |
| |
Aliases |
CHARAC17, CHRAC17, CHRAC2, YBL1, p17 |
| |
Entrez Gene ID |
|
| |
Gene Name |
DNA polymerase epsilon 3, accessory subunit |
| |
Chromosomal Location |
9q32 |
| |
HGNC ID |
|
| |
Summary |
POLE3 is a histone-fold protein that interacts with other histone-fold proteins to bind DNA in a sequence-independent manner. These histone-fold protein dimers combine within larger enzymatic complexes for DNA transcription, replication, and packaging.[supplied by OMIM, Apr 2004]
|
| |
e!Ensembl
|
| Protein Information |
| |
Protein Name |
DNA polymerase epsilon subunit 3, CHRAC-17, DNA polymerase II subunit 3, DNA polymerase epsilon p17 subunit, DNA polymerase epsilon subunit p17, arsenic transactivated protein, asTP, chromatin accessibility complex 17 kDa protein, chromatin accessibility complex subunit 2, histone fold protein CHRAC17, huCHRAC17, polymerase (DNA directed), epsilon 3 (p17 subunit), polymerase (DNA directed), epsilon 3, accessory subunit, polymerase (DNA) epsilon 3, accessory subunit |
| |
Function |
|
Accessory component of the DNA polymerase epsilon complex (PubMed:10801849). Participates in DNA repair and in chromosomal DNA replication (By similarity). Forms a complex with CHRAC1 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome-remodeling activity of ISWI/SNF2H and ACF1 (PubMed:10801849). |
|
| |
UniProt |
|
| |
Pfam |
| Pfam Accession |
Pfam ID |
| PF00808 |
CBFD_NFYB_HMF |
|
|
|
|
|
|
Interactions |
| | |
| STRING |
MINT |
IntAct |
| ENSP00000432282 |
Q01995 |
Q01995 |
|
| | |
View interactions
|
| |
| |
Associated Diseases
| Disease group | Disease Name | References |
| Endocrine System Diseases |
| PCOS |
|
| Neoplasms |
| Colorectal Cancer |
|
| Ovarian Cancer |
|
| Leukemia |
|
| Nutritional and Metabolic Diseases |
| Obesity |
|
|
|
References |
| |
| |
| Wei Lina, Xin Chunlei, Wang Wenjuan, Hao Cuifang |
| Department of Reproductive Medical, The Affiliated Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, PR China; Department of Reproductive Medical, Jining No. 1 People's Hospital, Jining, Shandong 272011, PR China.| Department of Hematology, Jining No. 1 People's Hospital, Jining, Shandong 272011, PR China.| Department of Reproductive Medical, The Affiliated Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, PR China.| Department of Reproductive Medical, The Affiliated Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, PR China. Electronic address: cuifang-hao@163.com. |
| Gene. 2018 Jun 30;661:85-94. doi: 10.1016/j.gene.2018.03.079. Epub 2018 Mar 28. |
Abstract
PURPOSE: This study aimed to screen key genes and pathways involved in obese polycystic ovary syndrome (PCOS), and predict drugs for treatment of obese PCOS via bioinformatics approaches. METHODS: Microarray dataset GSE10946 were downloaded from the Gene Expression Omnibus database, including 7 cumulus cell samples from obese PCOS patients and 6 lean control samples. Differentially expressed genes (DEGs) between obese PCOS and controls were obtained using Bayesian test after data preprocessing, followed by functional enrichment analyses for DEGs. Besides, protein-protein interaction (PPI) network and sub-network analyses were performed. Furthermore, drug prediction was carried out based on the DEGs. RESULTS: A total of 793 DEGs were identified in PCOS compared with control, including 352 up-regulated and 441 down-regulated DEGs. Specifically, upregulated RNA polymerase I subunit B (POLR1B), DNA polymerase epsilon 3, accessory subunit (POLE3), and DNA polymerase delta 3, accessory subunit (POLD3) were enriched in pathway of pyrimidine metabolism associated with obesity and PCOS, and 5-hydroxytryptamine receptor 2C (HTR2C) was enriched calcium signaling pathway. Additionally, 10 significant potential drugs, such as spironolactone targeting androgen receptor (AR), trimipramine targeting adrenoceptor beta 2 (ADRB2), and L-ornithine targeting ornithine decarboxylase antizyme 3 (OAZ3), were obtained. CONCLUSIONS: In conclusion, POLR1B, POLE3, POLD3, and HTR2C might play important roles in obese PCOS via involvement of pyrimidine metabolism and calcium signaling pathway. Moreover, AR, ADRB2, and OAZ3 might be targets of spironolactone, trimipramine, and L-ornithine in the treatment of obese PCOS. |
|
|
|
| |
| © 2019, Biomedical Informatics Centre, NIRRH |
National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai-400 012
Tel: 91-22-24192104, Fax No: 91-22-24139412
|
